27 Jan 2026 | 3 Mins Read
Onesource shares plunge 18% on Q3 losses from semaglutide delay
Flipitmoney
Onesource Specialty Pharma Ltd's shares dropped 18% after a weaker December quarter, caused by a delay in semaglutide approval in Canada, which led to revenue shortfall and margin pressure. Revenue fell 23% QoQ and 26% YoY to ₹290.34 crore. Q3 EBITDA plummeted 84% QoQ and 88% YoY to ₹17.32 crore. Despite this, guidance for FY28 remained unchanged.